<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479579</url>
  </required_header>
  <id_info>
    <org_study_id>10768</org_study_id>
    <nct_id>NCT04479579</nct_id>
  </id_info>
  <brief_title>Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery</brief_title>
  <official_title>Towards Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Abdominal or Pelvic Major Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, twin-center, cohort study in patients discharged from the hospital&#xD;
      after major abdominal or pelvic cancer surgery for cancer. This study is designed to evaluate&#xD;
      the adherence to extended deep vein thrombosis prophylaxis (DVT) with the direct oral&#xD;
      anticoagulant apixaban on the background of historical data from the investigator's center on&#xD;
      low-molecular-weight heparin (LMWH) substandard adherence in the same setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All guidelines have embraced the concept of extended DVT prophylaxis after major abdominal or&#xD;
      pelvic surgery for cancer, but the recommendation is consistently to use LMWH, which is more&#xD;
      complicated than orally available prophylaxis, more expensive and has poor adherence.&#xD;
&#xD;
      The patients will be identified in the pre-operative admission or in post-operative orders as&#xD;
      potentially eligible for extended prophylaxis. On the day of discharge a research assistant&#xD;
      or a research nurse will approach the patient, provide information about the study and obtain&#xD;
      written consent if the patient fulfills the eligibility criteria.&#xD;
&#xD;
      Each patient will be asked to take apixaban until postop day 29±1 and will be followed until&#xD;
      postop day 90±3. The total duration of the study from first patient in to last patient out is&#xD;
      expected to take 12 months.&#xD;
&#xD;
      At 1 week after discharge there is a telephone contact to ask about any side effects from&#xD;
      apixaban or bleeding events or signs of thromboembolism and to answer any questions from the&#xD;
      patient.&#xD;
&#xD;
      At postoperative Day +28-30 there is a telephone contact to ask about side effects, bleeding,&#xD;
      signs of venous thromboembolism (VTE), until what date the patient has taken apixaban and&#xD;
      estimate of missed doses using a standardized script. If the patient is still taking it,&#xD;
      instruction will be given to discontinue. Self-reported modified Morisky Medication Adherence&#xD;
      scale with 6 statements will be used At 90 days ±3 days there is the last telephone contact&#xD;
      to ask about bleeding events or signs of VTE. The study is complete for the patient. At the&#xD;
      time of Visit 4 the pharmacy that the patient uses will be contacted to provide dispensing&#xD;
      record for apixaban, in order to verify that the patient filled the prescription.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Actual">November 6, 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective cohort study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Filled prescription</measure>
    <time_frame>1 week</time_frame>
    <description>Percent of included patients that have filled their prescription for apixaban</description>
  </primary_outcome>
  <primary_outcome>
    <measure>At least 80% adherence</measure>
    <time_frame>30 days</time_frame>
    <description>Percent of patients with filled prescription that have at least 80% adherence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Venous thromboembolism post prophylaxis</measure>
    <time_frame>2 months</time_frame>
    <description>The event rate of venous thromboembolism during the 2 months after planned prophylaxis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of Venous thromboembolism during prophylaxis</measure>
    <time_frame>30 days</time_frame>
    <description>Symptomatic, objectively verified deep vein thrombosis of pulmonary embolism during 1st month</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Major bleeding during prophylaxis</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding during 1st month</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Clinically relevant non-major bleeding during prophylaxis</measure>
    <time_frame>30 days</time_frame>
    <description>Clinically relevant non-major bleeding during 1st month</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Death during prophylaxis</measure>
    <time_frame>30 days</time_frame>
    <description>Death during 1st month</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Neoplasms Malignant</condition>
  <condition>Surgery</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Prophylaxis</condition>
  <condition>Adherence, Medication</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apixaban for extended prophylaxis against VTE after discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 2.5 milligram</intervention_name>
    <description>apixaban 2.5 milligram twice daily from discharge until postoperative day 29 +/- 1 day</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>medication adherence assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of at least 18 years of age, discharged after hepato-biliary, colorectal or&#xD;
             gynecology-oncology abdominal/pelvic surgery (laparoscopic or open) for cancer and&#xD;
             considered at increased risk for VTE (e.g. previous history of VTE, residual cancer,&#xD;
             slow mobilization, obesity, comorbidities).&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to take tablets, even if crushed.&#xD;
&#xD;
          -  Active bleeding.&#xD;
&#xD;
          -  Venous thromboembolism diagnosed during the hospitalization.&#xD;
&#xD;
          -  Severe hepatic impairment (Child Pugh class C).&#xD;
&#xD;
          -  Severe renal failure on dialysis or with calculated creatinine clearance &lt;15 mL/min.&#xD;
&#xD;
          -  Platelet count &lt;50·109/L.&#xD;
&#xD;
          -  Concomitant treatment with azole-antimycotics, e.g., ketoconazole, itraconazole,&#xD;
             voriconazole, or posaconazole, and HIV protease inhibitors, e.g., ritonavir.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male, female, other</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Schulman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thrombosis Service, HHS-General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HHS-Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Serrano PE, Parpia S, Valencia M, Simunovic M, Bhandari M, Levine M. Incidence of delayed venous thromboembolic events in patients undergoing abdominal and pelvic surgery for cancer: a systematic review and meta-analysis. ANZ J Surg. 2019 Oct;89(10):1217-1223. doi: 10.1111/ans.15290. Epub 2019 Jun 18.</citation>
    <PMID>31210407</PMID>
  </reference>
  <reference>
    <citation>Serrano PE, Parpia S, Linkins LA, Elit L, Simunovic M, Ruo L, Bhandari M, Levine M. Venous Thromboembolic Events Following Major Pelvic and Abdominal Surgeries for Cancer: A Prospective Cohort Study. Ann Surg Oncol. 2018 Oct;25(11):3214-3221. doi: 10.1245/s10434-018-6671-7. Epub 2018 Jul 26.</citation>
    <PMID>30051364</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Sam Schulman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>apixaban</keyword>
  <keyword>abdominal</keyword>
  <keyword>pelvic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

